(Reuters) - U.S. regulators are continuing to probe whether a Sanofi-Aventis diabetes treatment raises cancer risk after determining that data from four studies was inconclusive.
(Reuters) - U.S. regulators are continuing to probe whether a Sanofi-Aventis diabetes treatment raises cancer risk after determining that data from four studies was inconclusive.
